Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy

Annunziata Dattola; Nicoletta  Bernardini; Elena  Campione; Emanuele  Amore; Simone  Amato; Giacomo  Caldarola; Clara  De Simone; Domenico Giordano; Gaia  Moretta; Vincenzo  Panasiti; Gianluca  Pagnanelli; Vincenzo  Roberti; Ruslana Gaeta  Shumak; Nevena Skroza; Ersilia  Tolino; Paola  Tribuzi; Salvatore  Zanframundo; Luca  Bianchi; Severino  Persechino; Concetta  Potenza; Giovanni  Pellacani; Ketty  Peris; Antonio Giovanni  Richetta

doi:10.5826/dpc.1502a4976

Authors

Annunziata Dattola Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
Nicoletta Bernardini Dermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy.
Elena Campione Dermatology Unit, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy
Emanuele Amore Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
Simone Amato Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
Giacomo Caldarola UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
Clara De Simone UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
Domenico Giordano Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University, Rome, Italy
Gaia Moretta Department of Dermatology, Istituto Dermopatico dell’Immacolata IRCCS Roma.
Vincenzo Panasiti Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; Operative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy
Gianluca Pagnanelli Department of Dermatology, Istituto Dermopatico dell’Immacolata IRCCS Roma.
Vincenzo Roberti Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy; Operative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy
Ruslana Gaeta Shumak ruslanagaetashumak@gmail.com
Nevena Skroza Dermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy
Ersilia Tolino Dermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy
Paola Tribuzi UOSD Ospedale Belcolle ASL Viterbo, Italy
Salvatore Zanframundo Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; Operative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy
Luca Bianchi Dermatology Unit, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy
Severino Persechino Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University, Rome, Italy
Concetta Potenza Dermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy
Giovanni Pellacani Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
Ketty Peris UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
Antonio Giovanni Richetta Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy

Keywords:

Bimekizumab, IL-17 Inhibition, Psoriatic Arthritis, IL-17, sensitives area, difficult to treat areas, psoriasis

Abstract

Introduction: Psoriasis significantly impacts a patient’s quality of life (QoL). Bimekizumab targets IL-17A and IL-17F, offering a broader blockade of the IL-17 pathway compared to other IL-17 inhibitors.

Objectives: This study evaluated the clinical efficacy of bimekizumab in bio-naive and bio-experienced patients with moderate-to-severe psoriasis over a 52-week period, with a focus on improvements across different body areas and QoL.

Methods: A retrospective analysis of real-world data was conducted on 132 patients from 8 medical centers. Efficacy was assessed using PASI scores, at baseline and at weeks 4, 16, 24, and 52, and DLQI scores. Patients were categorized based on prior biologic treatment experience.

Results: The mean PASI score decreased for all patients, from 14.41 at baseline to 0.18 at week 52, indicating substantial improvement. Area-specific PASI subscores showed significant reductions: head (3.24 to 0.13), upper limb (8.49 to 0), trunk (8.35 to 0.03), and lower limb (8.61 to 0.12). Complete skin clearence was achieved by week 16 in the majority of patients: 85% achieved complete skin clearance in the head, 90% in upper limbs, and 94% in both trunk and lower limbs. DLQI scores significantly improved from 13.57 at baseline to 0.86 at week 16, highlighting the early positive impact of bimekizumab in improving QoL. When comparing PASI scores between bio-naive and bio-experienced patients, no significant difference was found.

Conclusions: Bimekizumab demonstrates significant efficacy in reducing psoriasis severity across different body areas and improving QoL over a 52-week period. These findings support this robust treatment option for moderate-to-severe psoriasis.

References

Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. The BMJ. 2020;369. doi:10.1136/bmj.m1590

Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8. doi:10.3389/fmed.2021.743180

Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017;16(3):381-385. doi:10.1080/14740338.2017.1288714

Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.880201

Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9(AUG). doi:10.3389/fimmu.2018.01682

Bunte K, Beikler T. Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci. 2019;20(14). doi:10.3390/ijms20143394

Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10. doi:10.3389/fmed.2023.1243843

Warzyszak P, Małek R, Milczek M, et al. Psoriasis - a review of recent progress, characteristics, diagnostic management. Journal of Education, Health and Sport. 2022;13(2):149-155. doi:10.12775/jehs.2023.13.02.021

Bhatt TJ, Sanghavi UR, Zaveri ZH. Psoriasis: A Peer Review Article. www.ijfmr.com

Dasari S, Choudhary A, Madke B. Psoriasis: A Primer for General Physicians. Cureus. Published online April 24, 2023. doi:10.7759/cureus.38037

Camiña-Conforto G, Mateu-Arrom L, López-Ferrer A, Puig L. Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives. Patient Prefer Adherence. 2023;17:1541-1549. doi:10.2147/PPA.S350760

Mahmoud AM. Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients. Curr Med Res Opin. 2023;39(7):1031-1043. doi:10.1080/03007995.2023.2228613

Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;22(5):355-362. doi:10.1080/14740338.2023.2218086

Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. The Lancet. 2021;397(10273):475-486. doi:10.1016/S0140-6736(21)00126-4

Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. The Lancet. 2021;397(10273):487-498. doi:10.1016/S0140-6736(21)00125-2

Hagino T, Saeki H, Fujimoto E, Kanda N. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study. Journal of Dermatology. Published online May 1, 2024. doi:10.1111/1346-8138.17186

Orsini D, Malagoli P, Balato A, et al. Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience-IL PSO (Italian Landscape Psoriasis). doi:10.5826/dpc.1402a52

Merola JF, Gottlieb AB, Morita A, et al. AB1089 BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALS. In: BMJ; 2023:1766-1767. doi:10.1136/annrheumdis-2023-eular.3140

Warren RB, Strober B, Lebwohl M, et al. Abstract Citation ID: Ljad113.366 PS14 Bimekizumab Response up to 3 Years in Patients with Moderate-to-Severe Plaque Psoriasis Who Responded at Week 16: Post Hoc Results from the BE BRIGHT Open-Label Extension Trial.

Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. British Journal of Dermatology. 2023;188(6):749-759. doi:10.1093/bjd/ljad035

Natsis NE, Gottlieb AB. Bimekizumab for the treatment of psoriatic disease. Expert Opin Biol Ther. 2018;18(12):1193-1197. doi:10.1080/14712598.2018.1538351

Sharma, P., Jadon, D. R., McGonagle, D., Ink, B., Assudani, D., Taieb, V., & Coates, L. C.. (n.d.). BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO TNF INHIBITORS: IMPROVEMENTS OF PSARC OVER 16 WEEKS IN THE PHASE 3 BE COMPLETE TRIAL. P189. https://doi.org/kead104.230